Browse by UCL Departments and Centres
![[up]](/style/images/multi_up.png)
Up a levelGroup by: Author | Type
Number of items: 45.
A
|
Ainley, L;
Chavda, SJ;
Counsell, N;
Cheesman, S;
Newrick, F;
Horder, J;
Kyriakou, C;
... Yong, K; + view all
(2021)
DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation.
British Journal of Haematology
, 192
(3)
e73-e77.
10.1111/bjh.17248.
|
|
Arend, RC;
Monk, BJ;
Herzog, TJ;
Moore, KN;
Shapira-Frommer, R;
Ledermann, JA;
Tewari, KS;
... Penson, RT; + view all
(2021)
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
Gynecologic Oncology
10.1016/j.ygyno.2021.02.014.
(In press).
|
B
Bachy, E;
Rufibach, K;
Parreira, J;
Launonen, A;
Nielsen, T;
Hackshaw, A;
(2021)
Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation.
Advances in Therapy
10.1007/s12325-021-01738-2.
(In press).
|
 |
|
Baert, T;
Ferrero, A;
Sehouli, J;
O Donnell, DM;
González-Martín, A;
Joly, F;
Van der Velden, J;
... Ledermann, JA; + view all
(2021)
The systemic treatment of recurrent ovarian cancer revisited.
Annals of Oncology
10.1016/j.annonc.2021.02.015.
(In press).
|
|
Bentham, R;
Litchfield, K;
Watkins, TBK;
Lim, EL;
Rosenthal, R;
Martinez-Ruiz, C;
Hiley, CT;
... McGranahan, N; + view all
(2021)
Using DNA sequencing data to quantify T cell fraction and therapy response.
Nature
10.1038/s41586-021-03894-5.
(In press).
|
|
Biasco, L;
Izotova, N;
Rivat, C;
Ghorashian, S;
Richardson, R;
Guvenel, A;
Hough, R;
... Amrolia, PJ; + view all
(2021)
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients.
Nature Cancer
10.1038/s43018-021-00207-7.
(In press).
|
C
|
Camilleri, M;
Cuadrado, M;
Phillips, E;
Wilson, W;
Jenner, R;
Pang, G;
Kamora, S;
... Yong, K; + view all
(2021)
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
British Journal of Haematology
10.1111/bjh.17377.
(In press).
|
|
|
Camilleri, M;
Sive, J;
Wilson, W;
Pang, G;
Jenner, R;
Phillips, E;
Popat, R;
... Yong, K; + view all
(2021)
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.
British Journal of Haematology
, 192
(1)
E14-E16.
10.1111/bjh.17168.
|
|
Clamp, AR;
Lorusso, D;
Oza, AM;
Aghajanian, C;
Oaknin, A;
Dean, A;
Colombo, N;
... Ledermann, JA; + view all
(2021)
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
International Journal of Gynecological Cancer
10.1136/ijgc-2020-002240.
(In press).
|
|
Clark, JJ;
Dwyer, D;
Pinwill, N;
Clark, P;
Johnson, P;
Hackshaw, A;
(2021)
The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis.
The Lancet Oncology
, 22
(1)
pp. 66-73.
10.1016/S1470-2045(20)30619-7.
|
|
Concin, N;
Creutzberg, CL;
Vergote, I;
Cibula, D;
Mirza, MR;
Marnitz, S;
Ledermann, JA;
... Matias-Guiu, X; + view all
(2021)
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.
Virchows Archiv
, 478
pp. 153-190.
10.1007/s00428-020-03007-z.
|
|
Concin, N;
Matias-Guiu, X;
Vergote, I;
Cibula, D;
Mirza, MR;
Marnitz, S;
Ledermann, J;
... Creutzberg, CL; + view all
(2021)
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
International Journal Of Gynecological Cancer
, 31
(1)
pp. 12-39.
10.1136/ijgc-2020-002230.
|
|
|
Concin, N;
Matias-Guiu, X;
Vergote, I;
Cibula, D;
Mirza, MR;
Marnitz, S;
Ledermann, J;
... Creutzberg, CL; + view all
(2021)
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
Radiotherapy and Oncology
, 154
pp. 327-353.
10.1016/j.radonc.2020.11.018.
|
|
Cross, AJ;
Myles, J;
Greliak, P;
Hackshaw, A;
Halloran, S;
Benton, SC;
Addison, C;
... Raine, R; + view all
(2021)
Including a general practice endorsement letter with the testing kit in the Bowel Cancer Screening Programme: Results of a cluster randomised trial.
Journal of Medical Screening
10.1177/0969141321997480.
|
|
D
|
Dettorre, GM;
Dolly, S;
Loizidou, A;
Chester, J;
Jackson, A;
Mukherjee, U;
Zambelli, A;
... OnCovid study group; + view all
(2021)
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score.
Journal for ImmunoTherapy of Cancer
, 9
(3)
, Article e002277. 10.1136/jitc-2020-002277.
|
|
E
|
Elyashiv, O;
Wong, YNS;
Ledermann, JA;
(2021)
Frontline Maintenance Treatment for Ovarian Cancer.
Current Oncology Reports
, 23
(8)
, Article 97. 10.1007/s11912-021-01088-w.
|
|
G
|
Gleeson, M;
Counsell, N;
Cunningham, D;
Lawrie, A;
Clifton-Hadley, L;
Hawkes, E;
McMillan, A;
... Linch, D; + view all
(2021)
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.
British Journal of Haematology
, 192
(6)
pp. 1015-1019.
10.1111/bjh.16691.
|
H
|
Hackshaw, A;
Berg, CD;
(2021)
An efficient randomised trial design for multi-cancer screening blood tests: nested enhanced mortality outcomes of screening trial.
Lancet Oncology
, 22
(10)
pp. 1360-1362.
10.1016/S1470-2045(21)00204-7.
|
|
Hackshaw, A;
Cohen, SS;
Reichert, H;
Kansal, AR;
Chung, KC;
Ofman, JJ;
(2021)
Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK.
British Journal of Cancer
10.1038/s41416-021-01498-4.
(In press).
|
|
|
Hoskin, P;
Popova, B;
Schofield, O;
Brammer, C;
Robinson, M;
Brunt, AM;
Madhavan, K;
... Kirkwood, AA; + view all
(2021)
4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial.
The Lancet Oncology
, 22
(3)
pp. 332-340.
10.1016/S1470-2045(20)30686-0.
|
K
|
Kurtz, JE;
Gebski, V;
Sukhin, V;
Carey, M;
Kong, I;
Glasspool, RM;
Berek, JS;
... Friedlander, M; + view all
(2021)
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
Gynecologic Oncology
10.1016/j.ygyno.2021.02.018.
(In press).
|
L
|
Lacas, B;
Carmel, A;
Landais, C;
Wong, SJ;
Licitra, L;
Tobias, JS;
Burtness, B;
... MACH-NC Collaborative Group; + view all
(2021)
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.
Radiotherapy and Oncology
, 156
pp. 281-293.
10.1016/j.radonc.2021.01.013.
|
|
Leary, A;
Tan, D;
Ledermann, J;
(2021)
Immune checkpoint inhibitors in ovarian cancer: where do we stand?
Therapeutic Advances in Medical Oncology
, 13
10.1177/17588359211039899.
|
|
|
Ledermann, JA;
Embleton-Thirsk, AC;
Perren, TJ;
Jayson, GC;
Rustin, GJS;
Kaye, SB;
Hirte, H;
... ICON6 collaborators, .; + view all
(2021)
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
ESMO Open
, 6
(2)
, Article 100043. 10.1016/j.esmoop.2020.100043.
|
|
|
Lee, CK;
Friedlander, ML;
Tjokrowidjaja, A;
Ledermann, JA;
Coleman, RL;
Mirza, MR;
Matulonis, UA;
... Scott, CL; + view all
(2021)
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Cancer
10.1002/cncr.33517.
(In press).
|
M
|
Martinez-Calle, N;
Kirkwood, AA;
Lamb, M;
Smith, A;
Khwaja, J;
Manos, K;
Shrubsole, C;
... Fox, CP; + view all
(2021)
Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.
Advances in Therapy
10.1007/s12325-021-01764-0.
|
|
|
McCulloch, R;
Lewis, D;
Crosbie, N;
Eyre, TA;
Bolam, S;
Arasaretnam, A;
Creasey, T;
... Rule, S; + view all
(2021)
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
British Journal of Haematology
10.1111/bjh.17363.
|
|
|
Mikhaeel, NG;
Cunningham, D;
Counsell, N;
McMillan, A;
Radford, JA;
Ardeshna, KM;
Lawrie, A;
... Barrington, SF; + view all
(2021)
FDG‐PET/CT after two cycles of R‐CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study.
British Journal of Haematology
, 192
(3)
pp. 504-513.
10.1111/bjh.16875.
|
|
Monk, BJ;
Colombo, N;
Oza, AM;
Fujiwara, K;
Birrer, MJ;
Randall, L;
Poddubskaya, EV;
... Ledermann, JA; + view all
(2021)
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
The Lancet Oncology
, 22
(9)
pp. 1275-1289.
10.1016/S1470-2045(21)00342-9.
|
|
Morgan, RD;
McNeish, IA;
Cook, AD;
James, EC;
Lord, R;
Dark, G;
Glasspool, RM;
... Clamp, AR; + view all
(2021)
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
The Lancet Oncology
, 22
(2)
pp. 277-288.
10.1016/S1470-2045(20)30591-X.
|
|
O
|
Oaknin, A;
Oza, AM;
Lorusso, D;
Aghajanian, C;
Dean, A;
Colombo, N;
Weberpals, JI;
... Coleman, RL; + view all
(2021)
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
Cancer Medicine
10.1002/cam4.4260.
(In press).
|
|
P
|
Petit, C;
Lacas, B;
Pignon, J-P;
Le, QT;
Grégoire, V;
Grau, C;
Hackshaw, A;
... MACH-NC and MARCH Collaborative Groups; + view all
(2021)
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis.
Lancet Oncology
, 22
(5)
pp. 727-736.
10.1016/S1470-2045(21)00076-0.
|
|
Pinato, DJ;
Scotti, L;
Gennari, A;
Colomba-Blameble, E;
Dolly, S;
Loizidou, A;
Chester, J;
... Cortellini, A; + view all
(2021)
Determinants of enhanced vulnerability to COVID-19 in UK cancer patients: a European Study.
European Journal of Cancer
10.1016/j.ejca.2021.03.035.
(In press).
|
|
Popat, R;
Counsell, N;
de Tute, R;
De-Silva, D;
Phillips, EH;
Cavenagh, JD;
Adedayo, T;
... Yong, K; + view all
(2021)
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
British Journal of Haematology
10.1111/bjh.17391.
(In press).
|
|
Poveda, A;
Floquet, A;
Ledermann, JA;
Asher, R;
Penson, RT;
Oza, AM;
Korach, J;
... SOLO2/ENGOT-Ov21 investigators, .; + view all
(2021)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncology
10.1016/S1470-2045(21)00073-5.
(In press).
|
|
Pujade-Lauraine, E;
Fujiwara, K;
Ledermann, JA;
Oza, AM;
Kristeleit, R;
Ray-Coquard, I-L;
Richardson, GE;
... Monk, BJ; + view all
(2021)
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
The Lancet Oncology
, 22
(7)
pp. 1034-1046.
10.1016/S1470-2045(21)00216-3.
|
Q
|
Quaife, SL;
Waller, J;
Dickson, JL;
Brain, KE;
Kurtidu, C;
McCabe, J;
Hackshaw, A;
... Janes, SM; + view all
(2021)
Psychological Targets for Lung Cancer Screening Uptake: A Prospective Longitudinal Cohort Study.
Journal of Thoracic Oncology
10.1016/j.jtho.2021.07.025.
(In press).
|
R
|
Rockall, AG;
Barwick, TD;
Wilson, W;
Singh, N;
Bharwani, N;
Sohaib, A;
Nobbenhuis, M;
... Study Group, M; + view all
(2021)
Diagnostic accuracy of FET-PET/CT, FDG-PET/CT and diffusion-weighted MRI in detection of nodal metastases in surgically treated endometrial and cervical carcinoma.
Clinical Cancer Research
10.1158/1078-0432.ccr-21-1834.
(In press).
|
|
|
Russell, J;
Collins, A;
Fowler, A;
Karanth, M;
Saha, C;
Docherty, S;
Padayatty, J;
... Follows, GA; + view all
(2021)
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial.
Annals of Hematology
, 100
pp. 1049-1058.
10.1007/s00277-021-04460-9.
|
|
T
|
Tjokrowidjaja, A;
Friedlander, M;
Lord, SJ;
Asher, R;
Rodrigues, M;
Ledermann, JA;
Matulonis, UA;
... Lee, CK; + view all
(2021)
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
European Journal of Cancer
, 154
pp. 190-200.
10.1016/j.ejca.2021.06.024.
|
W
|
Wall, EC;
Wu, M;
Harvey, R;
Kelly, G;
Warchal, S;
Sawyer, C;
Daniels, R;
... Bauer, DL; + view all
(2021)
AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC.
The Lancet
10.1016/S0140-6736(21)01462-8.
(In press).
|
|
|
Wall, EC;
Wu, M;
Harvey, R;
Kelly, G;
Warchal, S;
Sawyer, C;
Daniels, R;
... Bauer, DLV; + view all
(2021)
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.
The Lancet
10.1016/s0140-6736(21)01290-3.
(In press).
|
|
|
Watts, C;
Ashkan, K;
Jenkinson, MD;
Price, SJ;
Santarius, T;
Matys, T;
Zhang, TT;
... Counsell, N; + view all
(2021)
An evaluation of the tolerability and feasibility of combining 5-amino-levulinic acid (5-ala) with bcnu wafers in the surgical management of primary glioblastoma.
Cancers
, 13
, Article 3241. 10.3390/cancers13133241.
|
|
|
Wong, Yien Ning Sophia;
(2021)
Identification of urine derived lymphocytes as a non-invasive measure of the tumour immune microenvironment in bladder cancer.
Doctoral thesis (Ph.D), UCL (University College London).
|
|
Wood, GE;
Ledermann, JA;
(2021)
Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer.
Best Practice & Research Clinical Obstetrics & Gynaecology
10.1016/j.bpobgyn.2021.09.002.
(In press).
|
